Move over tamoxifen; make room for letrozole

Article

In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, results in a higher 5-year disease-free survival (DFS) rate (84% vs. 81.4%) and in a significantly reduced risk of an event ending a DFS period (hazard ratio, 0.81). Such events included a cancer that recurred locally, regionally, or at a distant site, a new invasive cancer in the contralateral breast, or any second non-breast cancer, or death from a prior cancer.

In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, results in a higher 5-year disease-free survival (DFS) rate (84% vs. 81.4%) and in a significantly reduced risk of an event ending a DFS period (hazard ratio, 0.81). Such events included a cancer that recurred locally, regionally, or at a distant site, a new invasive cancer in the contralateral breast, or any second non-breast cancer, or death from a prior cancer.

The findings come from The Breast International Group (BIG) 1-98 study, a randomized, Phase III, double-blind trial of over 8,000 women that looked at treatment with letrozole alone, letrozole followed by tamoxifen, tamoxifen alone, and tamoxifen followed by letrozole.

In terms of adverse events, the women in the two groups that received letrozole initially were less likely to develop thromboembolism, endometrial cancer, and vaginal bleeding, but more likely to have skeletal and cardiac complications and hypercholesterolemia.

Recent Videos
Experts discuss how maternal diet during pregnancy impacts infant development | Image Credit: ohsu.edu.
April Christina’s endometriosis journey: Diagnosis delays, treatment, and support | Image Credit: © mdaros - © mdaros - stock.adobe.com.
1 expert is featured in this series.
Giovanni Traverso, PhD, highlights contraceptive implants through small needle | Image Credit: meche.mit.edu
Ryan Haumschild, PharmD
1 expert is featured in this series.
How sex differences impact treatment efficacy for chronic pain | Image Credit: profiles.ucalgary.ca.
Tuan Trang, PhD, discusses biological differences in chronic pain between men and women | Image Credit: profiles.ucalgary.ca.
1 expert is featured in this series.
How the Flyte device revolutionizes SUI management | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.